Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnAISquareMore
Jena Acquisition II swings to Q2 profit of $1.88 million; net loss narrows to $2.98 million in H1 FY26

Jena Acquisition II swings to Q2 profit of $1.88 million; net loss narrows to $2.98 million in H1 FY26

ReutersReuters2026/08/14 20:13
  • Jena Acquisition Corporation II posted net income of USD 1.88 million for the quarter ended June 30, 2026.
  • Dividend and interest income in the trust account totaled USD 2.1 million, partially offset by formation and administrative costs of USD 222,741.
  • Net income for the six months ended June 30, 2026 was USD 2.98 million on USD 4.18 million of trust interest and dividends.
  • Cash outside the trust account was USD 66,988 at June 30, 2026, with working capital of USD 210,395.
  • NYSE flagged non-compliance with the 300 public shareholders requirement; a plan was submitted to regain compliance within 18 months.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jena Acquisition Corporation II published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-090044), on August 14, 2026, and is solely responsible for the information contained therein.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Electra Therapeutics (ETRA.US) submits US IPO application, leveraging the biotech IPO boom to advance new drug development for immune diseases and cancer.

Electra Therapeutics Inc. has officially filed for an initial public offering (IPO), aiming to leverage the strong IPO performance of the biotechnology sector this year to raise funds for its clinical-stage pipeline of drugs targeting immune-mediated diseases and cancer.

智通财经2026/08/29 03:22
Electra Therapeutics (ETRA.US) submits US IPO application, leveraging the biotech IPO boom to advance new drug development for immune diseases and cancer.

Blue Owl (OWL.US) teams up with PIMCO to tailor a $2.4 billion GPU financing for IREN (IREN.US)

A $2.4 billions debt financing round, led by funds under Blue Owl Capital Inc., has been finalized. The funds will be allocated to cloud service provider IREN Ltd. to purchase NVIDIA's Blackwell Ultra GPUs, supporting the development of its data center campus in Canada.

智通财经2026/08/29 02:27
Blue Owl (OWL.US) teams up with PIMCO to tailor a $2.4 billion GPU financing for IREN (IREN.US)